BD Announces Results For 2018 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2019 Guidance
- As reported, full fiscal year revenues of $15.983 billion increased 32.2 percent.
- On a comparable, currency-neutral basis, revenues increased 5.8 percent for the full fiscal year.
- As reported, full fiscal year diluted earnings per share of $0.60 decreased 87.0 percent.
- As adjusted, full fiscal year diluted earnings per share of $11.01 increased 16.1 percent, or 12.3 percent on a currency-neutral basis.
- The company expects full fiscal year 2019 revenues to increase 8.5 to 9.5 percent as reported, or 5.0 to 6.0 percent on a comparable, currency-neutral basis.
- As adjusted, the company expects full fiscal year 2019 diluted earnings per share to be between $12.05 and $12.15, resulting in growth of approximately 13.0 to 14.0 percent on a currency-neutral basis, which includes an adverse impact of approximately 600 basis points related to headwinds and divestitures. This represents growth of approximately 10.0 percent including the estimated unfavorable impact of foreign currency.
- Fiscal 2019 earnings per share expectations include high-single digit accretion from the C. R. Bard acquisition.
PR Newswire

FRANKLIN LAKES, N.J., Nov. 6, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.402 billion for the fourth fiscal quarter ended September 30, 2018. This represents an increase of 39.0 percent from the prior-year period, which is primarily due to the acquisition of C. R. Bard. On a comparable, currency-neutral basis that includes the revenues of C. R. Bard in the current and prior year, fourth quarter revenues increased 8.4 percent over the prior-year period. For the full fiscal year ended September 30, 2018, revenues of $15.983 billion increased 32.2 percent from the prior-year period, primarily due to the acquisition of C. R. Bard. On a comparable, currency-neutral basis that includes the revenues of C. R. Bard in the current and prior year, full fiscal year revenues of $16.930 billion grew 5.8 percent. This includes an estimated 60 basis point adverse impact from the previously disclosed change in the U.S. dispensing business model and the estimated sales impact from Hurricane Maria in Puerto Rico on Bard's business during BD's first fiscal quarter.

"Fiscal 2018 was a historic year for BD with the successful completion of the acquisition of C. R. Bard. We are extremely proud of our strong fourth quarter and fiscal year results, which demonstrate how agile we can be as an organization while executing concurrently on two transformative acquisitions," said Vincent A. Forlenza, Chairman and CEO. "We enter fiscal 2019 with continued strong momentum and confidence in our ability to execute on our strategy, deliver on our commitments and create value for our shareholders."

Fourth Quarter and Twelve-Month Fiscal 2018 Operating Results
As reported, diluted earnings per share for the fourth quarter were $(0.64), compared with $1.24 in the prior-year period. This represents a decrease of 151.6 percent and is primarily due to purchase accounting expenses relating to acquisitions and additional tax expense relating to new U.S. tax legislation. Adjusted diluted earnings per share were $2.93, compared with $2.40 in the prior-year period. This represents an increase in adjusted diluted earnings per share of 22.1 percent, or 24.6 percent on a currency-neutral basis.

For the twelve-month period ended September 30, 2018, as reported, diluted earnings per share were $0.60, compared with $4.60 in the prior-year period. This represents a decrease of 87.0 percent and is primarily due to purchase accounting and other expenses relating to acquisitions and additional tax expense relating to new U.S. tax legislation, offset by a non-cash charge in the prior year related to the change in the U.S. dispensing model. Adjusted diluted earnings per share were $11.01, compared with $9.48 in the prior-year period. This represents an increase in adjusted diluted earnings per share of 16.1 percent, or 12.3 percent on a currency-neutral basis.

Segment Results
In the BD Medical segment, as reported, worldwide revenues for the quarter of $2.346 billion increased 20.8 percent over the prior-year period, primarily due to the acquisition of C. R. Bard. On a comparable, currency-neutral basis, BD Medical revenues increased 10.1 percent over the prior-year period. The segment's results were driven by strong performance in the Medication Management Solutions, Medication Delivery Solutions and Pharmaceutical Systems units.

For the twelve-month period ended September 30, 2018, BD Medical revenues were $8.616 billion as reported, an increase of 16.1 percent over the prior-year period. On a comparable, currency-neutral basis, BD Medical revenues of $8.826 billion increased 5.6 percent over the prior-year period, which includes an estimated 80 basis point adverse impact from the change in the U.S. dispensing business model.

In the BD Life Sciences segment, as reported, worldwide revenues for the quarter were $1.108 billion, an increase of 5.5 percent over the prior-year period, or 6.9 percent on a currency-neutral basis. Revenue growth reflects strong performance across the segment.

For the twelve-month period ended September 30, 2018, BD Life Sciences revenues were $4.330 billion as reported, an increase of 8.6 percent over the prior-year period, or an increase of 6.8 percent on a currency-neutral basis.

In the BD Interventional segment, as reported, worldwide revenues for the quarter were $0.948 billion. On a comparable, currency-neutral basis, revenues increased 6.0 percent over the prior-year period. The segment's results reflect strong performance in the Peripheral Intervention and Urology and Critical Care units.

For the twelve-month period ended September 30, 2018, BD Interventional revenues were $3.037 billion as reported. On a comparable, currency-neutral basis, BD Interventional revenues of $3.774 billion increased 5.2 percent, which includes an estimated 90 basis point adverse impact from Hurricane Maria in Puerto Rico on Bard's business during BD's first fiscal quarter.

Geographic Results
As reported, fourth quarter revenues in the U.S. of $2.448 billion increased 48.9 percent over the prior-year period, primarily due to the acquisition of C. R. Bard. On a comparable basis, U.S. revenues increased 8.7 percent over the prior-year period. Growth in the U.S. was primarily driven by very strong performance in the Medication Management Solutions and Pharmaceutical Systems units within the BD Medical segment.

As reported, revenues outside of the U.S. of $1.954 billion increased 28.4 percent from the prior-year period, primarily due to the acquisition of C. R. Bard. On a comparable, currency-neutral basis, revenues outside of the U.S. increased 7.9 percent over the prior-year period. International revenue growth was driven by strong performance from all three segments.

For the twelve-month period ended September 30, 2018, U.S. revenues were $8.768 billion as reported, an increase of 34.8 percent over the prior-year period. On a comparable basis, U.S. revenues of $9.364 billion increased 5.0 percent over the prior-year period, which includes an estimated 100 basis point adverse impact from the change in the U.S. dispensing business model and Hurricane Maria. As reported, revenues outside of the U.S. of $7.215 billion increased 29.1 percent over the prior-year period. On a comparable, currency-neutral basis, revenues outside the U.S. of $7.566 billion increased 7.0 percent over the prior-year period.

Fiscal 2019 Outlook for Full Year
As reported, the company expects full fiscal year 2019 revenues to increase 8.5 to 9.5 percent, primarily due to the C. R. Bard acquisition. The company estimates full fiscal year 2019 revenues will increase 5.0 to 6.0 percent on a comparable, currency-neutral basis that includes the revenues of C. R. Bard in fiscal 2019 as well as the full 2018 fiscal year.

The company expects adjusted diluted earnings per share to be between $12.05 and $12.15, resulting in growth of approximately 13.0 to 14.0 percent on a currency-neutral basis, which includes an adverse impact of approximately 600 basis points related to headwinds and divestitures. This represents growth of approximately 10.0 percent including the estimated unfavorable impact of foreign currency over fiscal 2018 adjusted diluted earnings per share of $11.01. Fiscal 2019 earnings per share expectations include high-single digit accretion from the C. R. Bard acquisition.

Estimated adjusted diluted earnings per share for fiscal 2019 includes an estimate of the impact of adopting ASU 2014-09, Revenue from Contracts with Customers, as of October 1, 2018, and excludes potential charges or gains that may be recorded during the fiscal year, such as, among other things, the non-cash amortization of intangible assets, acquisition-related charges, and certain tax, litigation and regulatory compliance matters. BD does not attempt to provide reconciliations of forward-looking non-GAAP earnings guidance to the comparable GAAP measure because the impact and timing of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of BD's financial performance.

Conference Call Information
A conference call regarding BD's fourth quarter results will be broadcast live on BD's website, www.bd.com/investors , along with related slides, at 8:00 a.m. (ET) Tuesday, November 6, 2018. The conference call will be available for replay on BD's website, www.bd.com/investors , or at 1-800-585-8367 (domestic) and 1-404-537-3406 (international) through the close of business on Tuesday, November 13, 2018, confirmation number 3197559.

Non-GAAP Financial Measures/Financial Tables
This news release contains certain non-GAAP financial measures. Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Percentages and earnings per share amounts presented are calculated from the underlying amounts.

All "comparable" basis revenue growth rates relating to fiscal years 2018 and 2019 presented throughout this release include the results of C. R. Bard, Inc. ("Bard") in the current and prior-year periods and are further adjusted for certain items as detailed in the attached tables. Beginning in the second quarter of fiscal year 2018, the company's organizational structure was based upon three principal business segments: BD Medical ("Medical"), BD Life Sciences ("Life Sciences") and BD Interventional ("Interventional"). The Interventional segment was added upon the company's completion of its acquisition of Bard, and this new segment includes the majority of Bard's product offerings and certain product offerings which were previously reported in the Medical segment. Certain of Bard's product offerings are included under the Company's Medical segment, specifically within the new Medication Delivery Solutions unit, which was formerly the Medical segment's Medication and Procedural Solutions unit. Prior-year amounts have been revised to reflect the movement of certain product offerings which were previously reported in the Medical segment and which are now reported in the Interventional segment, as discussed above. Current and prior-year adjusted diluted earnings per share results exclude, among other things, the impact of purchase accounting adjustments (including the non-cash amortization of acquisition-related intangible assets); integration, restructuring and transaction costs; the reversal of a litigation reserve; and the loss on debt extinguishment. These measures are also provided on a currency-neutral basis after eliminating the effect of foreign currency translation, where applicable. Foreign currency-neutral percentages are calculated by converting the current-period local currency financial results using the prior period foreign currency exchange rates and comparing these adjusted amounts to the current-period results. Reconciliations of these amounts to the most directly comparable GAAP measures are included in the tables at the end of this release. As previously announced, comparable historical revenue schedules inclusive of Bard for BD's 2016 and 2017 fiscal years, and the first quarter of BD's 2018 fiscal year, are available on the Investor page of BD's website, www.bd.com/investors .

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to better diagnose disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com.

***

This press release, including the section entitled "Fiscal 2019 Outlook for Full Year", contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues and earnings per share. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially. These factors include, but are not limited to: risks relating to the integration of the C.R. Bard operations, products and employees into BD and the possibility that the anticipated synergies and other benefits of the proposed acquisition will not be realized or will not be realized within the expected timeframe; uncertainty regarding the impact of the recent U.S. tax reform; legislative or regulatory changes to the U.S. healthcare system, potential cuts in governmental healthcare spending or measures to contain healthcare costs, each of which could result in reduced demand for our products or downward pricing pressure; changes in interest or foreign currency exchange rates; adverse changes in regional, national or foreign economic conditions, particularly in emerging markets, including any impact on our ability to access credit markets and finance our operations, the demand for our products and services, utilization rates or otherwise, or our suppliers' ability to provide products needed for our operations; new or changing laws and regulations impacting our business (including the imposition of tariffs or changes in laws impacting international trade) or changes in enforcement practices with respect to such laws; our ability to successfully integrate any businesses we acquire; the adverse impact of cyber-attacks on our information systems or products; competitive factors including technological advances and new products introduced by competitors; interruptions in our supply chain or manufacturing processes; pricing and market pressures; difficulties inherent in product development, delays in product introductions and uncertainty of market acceptance of new products; adverse changes in geopolitical conditions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; product efficacy or safety concerns resulting in product recalls or actions being taken by the FDA or other regulators; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; risks relating to our ability to continue to successfully integrate CareFusion's operations in order to fully obtain the benefits of the transaction; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); future healthcare reform outside the U.S., including changes in government pricing and reimbursement policies or other cost containment reforms; and issuance of new or revised accounting standards, as well as other factors discussed in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.


            BECTON DICKINSON AND COMPANY
    CONSOLIDATED INCOME STATEMENTS
    (Unaudited; Amounts in millions, except share and per share data)




                                                                        
        Three Months Ended September 30,


                                                                   2018                       2017             % Change




            REVENUES                                                     $
        4,402                                   $
      3,166               39.0





            Cost of products sold                                2,311                                  1,612                         43.4


             Selling and administrative expense                   1,103                                    774                         42.6


             Research and development expense                       278                                    221                         25.7


             Acquisitions and other restructurings                  140                                    111                         25.9



            Other operating expense, net                                                                   5                      (100.0)


             TOTAL OPERATING COSTS AND EXPENSES                   3,832                                  2,723                         40.7




            OPERATING INCOME                                       570                                    443                         28.7





            Interest expense                                     (181)                                 (156)                        15.6



            Interest income                                          9                                     45                       (79.8)



            Other income (expense), net                             16                                    (7)                       339.9




            INCOME BEFORE INCOME TAXES                             415                                    326                         27.4


             Income tax provision (benefit)                         550                                    (1)                    44,493.5




            NET (LOSS) INCOME                                    (135)                                   327                      (141.3)



            Preferred stock dividends                             (38)                                  (38)


             NET (LOSS) INCOME APPLICABLE TO COMMON
              SHAREHOLDERS                                                $
        (173)                                    $
      289            (159.8)






            EARNINGS PER SHARE


             Basic (Loss) Earnings per Share                             $
        (0.64)                                   $
      1.27            (150.4)


             Diluted (Loss) Earnings per Share                           $
        (0.64)                                   $
      1.24            (151.6)




             AVERAGE SHARES OUTSTANDING (in
              thousands)



            Basic                                              268,500                                228,218



            Diluted                                            268,500                                232,657


              BECTON DICKINSON AND COMPANY
    CONSOLIDATED INCOME STATEMENTS
    (Unaudited; Amounts in millions, except share and per share data)




                                                                        
         Twelve Months Ended September 30,


                                                                   2018                       2017              % Change




              REVENUES                                                 $
         15,983                                    $
       12,093            32.2





              Cost of products sold                              8,721                                  6,151                           41.8


               Selling and administrative expense                 4,015                                  2,925                           37.3


               Research and development expense                   1,006                                    774                           29.9


               Acquisitions and other restructurings                744                                    354                          110.1


               Other operating expense, net                                                               410                        (100.0)


               TOTAL OPERATING COSTS AND EXPENSES                14,487                                 10,615                           36.5




              OPERATING INCOME                                   1,497                                  1,478                            1.3





              Interest expense                                   (706)                                 (521)                          35.5



              Interest income                                       65                                     76                         (15.0)



              Other income (expense), net                          318                                   (57)                         655.9



              INCOME BEFORE INCOME TAXES                         1,173                                    976                           20.2


               Income tax provision (benefit)                       862                                  (124)                         795.8



              NET INCOME                                           311                                  1,100                         (71.7)



              Preferred stock dividends                          (152)                                  (70)                         115.6


               NET INCOME APPLICABLE TO COMMON
                SHAREHOLDERS                                               $
         159                                     $
       1,030          (84.5)






              EARNINGS PER SHARE



              Basic Earnings per Share                                   $
         0.62                                      $
       4.70          (86.8)



              Diluted Earnings per Share                                 $
         0.60                                      $
       4.60          (87.0)




               AVERAGE SHARES OUTSTANDING (in
                thousands)



              Basic                                            258,354                                218,943



              Diluted                                          264,621                                223,588


              BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS - UNITED STATES
    Three Months Ended September 30,
    (Unaudited; Amounts in millions)




                                                              
              A                       
              B                        C=(A-B)/B



                                                                      2018                                2017                         % Change




              
                BD MEDICAL

    ---

               Medication Delivery Solutions (a)                               $
              512                                                      $
              352                  45.7


               Medication Management Solutions                         542                                           440                                                  23.2



              Diabetes Care                                           149                                           147                                                   1.7



              Pharmaceutical Systems                                  118                                            96                                                  22.1



              TOTAL                                                         $
              1,322                                                    $
              1,035                  27.7





                            BD LIFE SCIENCES

    ---


              Preanalytical Systems                                           $
              196                                                      $
              189                   3.7



              Diagnostic Systems                                      159                                           151                                                   5.9



              Biosciences                                             125                                           123                                                   1.6



              TOTAL                                                           $
              481                                                      $
              463                   3.8





                            BD INTERVENTIONAL

    ---


              Surgery (a)                                                     $
              259                                                      $
              143                
       NM



              Peripheral Intervention (a)                             201                                             3                                                 
          NM



              Urology and Critical Care                               186                                                                                              
          NM




              TOTAL                                                           $
              646                                                      $
              146                
       NM






              TOTAL UNITED STATES                                           $
              2,448                                                    $
              1,644                  48.9





               (a)  The presentation of prior-period amounts reflects a reclassification of $146 million associated with the movement, effective on January 1, 2018, of
                certain product offerings from the Medical segment to the Interventional segment.


              BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS - INTERNATIONAL
    Three Months Ended September 30, (continued)
    (Unaudited; Amounts in millions)




                                                                                                                                                                                                              D=(A-B)/B                          E=(A-B-
                                                                                                                                                                                                                                                   C)/B



                                                                                          
              A                       
              B                   
              C                                 
              % Change



                                                                                                  2018                                2017                           FX Impact                                  Reported                             FXN




              
                BD MEDICAL

    ---


              Medication Delivery Solutions (a)                                                           $
              454                                                        $
              369                                                        $
       (12)        23.0            26.4



              Medication Management Solutions                                                     149                                             131                                                                (1)                                     14.1         15.0



              Diabetes Care                                                                       135                                             136                                                                (3)                                    (0.8)         1.8



              Pharmaceutical Systems                                                              285                                             271                                                                  1                                       5.4          4.9



              TOTAL                                                                                     $
              1,025                                                        $
              908                                                        $
       (16)        12.9            14.6






              
                BD LIFE SCIENCES

    ---


              Preanalytical Systems                                                                       $
              197                                                        $
              189                                                         $
       (8)         4.4             8.6



              Diagnostic Systems                                                                  224                                             208                                                                (5)                                      7.6          9.8



              Biosciences                                                                         206                                             191                                                                (3)                                      8.2          9.6



              TOTAL                                                                                       $
              627                                                        $
              588                                                        $
       (15)         6.7             9.3






              
                BD INTERVENTIONAL

    ---


              Surgery (a)                                                                                  $
              69                                                         $
              24                                                         $
       (1)      
       NM          
      NM



              Peripheral Intervention (a)                                                         148                                               2                                                                (1)                                      
         NM           
      NM



              Urology and Critical Care                                                            85                                                                                                                                                        
         NM           
      NM



              TOTAL                                                                                       $
              302                                                         $
              26                                                         $
       (2)      
       NM          
      NM






              TOTAL INTERNATIONAL                                                                       $
              1,954                                                      $
              1,522                                                        $
       (33)        28.4            30.6






              (a)  The presentation of prior-period amounts reflects a reclassification of $26 million associated with the movement, effective on January 1, 2018, of certain product offerings from the Medical segment to the Interventional segment.


              BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS - TOTAL
    Three Months Ended September 30, (continued)
    (Unaudited; Amounts in millions)




                                                                                                                                                                                                              D=(A-B)/B                          E=(A-B-
                                                                                                                                                                                                                                                   C)/B



                                                                                          
              A                       
              B                   
              C                                 
              % Change



                                                                                                  2018                                2017                           FX Impact                                  Reported                             FXN




              
                BD MEDICAL

    ---


              Medication Delivery Solutions (a)                                                           $
              967                                                        $
              721                                                         $
      (12)        34.1            35.8



              Medication Management Solutions                                                     692                                             571                                                                (1)                                     21.1         21.3



              Diabetes Care                                                                       285                                             283                                                                (3)                                      0.5          1.7



              Pharmaceutical Systems                                                              403                                             367                                                                  1                                       9.8          9.4



              TOTAL                                                                                     $
              2,346                                                      $
              1,943                                                         $
      (16)        20.8            21.6






              
                BD LIFE SCIENCES

    ---


              Preanalytical Systems                                                                       $
              393                                                        $
              378                                                          $
      (8)         4.0             6.1



              Diagnostic Systems                                                                  384                                             359                                                                (5)                                      6.9          8.2



              Biosciences                                                                         331                                             314                                                                (3)                                      5.6          6.4



              TOTAL                                                                                     $
              1,108                                                      $
              1,051                                                         $
      (15)         5.5             6.9






              
                BD INTERVENTIONAL

    ---


              Surgery (a)                                                                                 $
              328                                                        $
              167                                                          $
      (1)      
       NM          
      NM



              Peripheral Intervention (a)                                                         348                                               5                                                                (1)                                      
         NM           
      NM



              Urology and Critical Care                                                           271                                                                                                                                                        
         NM           
      NM



              TOTAL                                                                                       $
              948                                                        $
              172                                                          $
      (2)      
       NM          
      NM






              TOTAL REVENUES                                                                            $
              4,402                                                      $
              3,166                                                         $
      (33)        39.0            40.1






              (a)  The presentation of prior-period amounts reflects a reclassification of $172 million associated with the movement, effective on January 1, 2018, of certain product offerings from the Medical segment to the Interventional segment.


              BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS - UNITED STATES
    Twelve Months Ended September 30,
    (Unaudited; Amounts in millions)




                                                              
              A                       
              B                        C=(A-B)/B



                                                                      2018                                2017                         % Change




              
                BD MEDICAL

    ---

               Medication Delivery Solutions (a)                             $
              1,892                                                    $
              1,378                  37.3


               Medication Management Solutions                       1,957                                         1,843                                                   6.2



              Diabetes Care                                           564                                           546                                                   3.2



              Pharmaceutical Systems                                  357                                           328                                                   8.9



              TOTAL                                                         $
              4,770                                                    $
              4,095                  16.5





                            BD LIFE SCIENCES

    ---


              Preanalytical Systems                                           $
              761                                                      $
              741                   2.6



              Diagnostic Systems                                      678                                           622                                                   8.9



              Biosciences                                             475                                           455                                                   4.6



              TOTAL                                                         $
              1,914                                                    $
              1,818                   5.3





                            BD INTERVENTIONAL

    ---


              Surgery (a)                                                     $
              946                                                      $
              577                
       NM



              Peripheral Intervention (a)                             594                                            14                                                 
          NM



              Urology and Critical Care                               544                                                                                              
          NM



              TOTAL                                                         $
              2,084                                                      $
              591                
       NM






              TOTAL UNITED STATES                                           $
              8,768                                                    $
              6,504                  34.8





               (a)  The presentation of prior-period amounts reflects a reclassification of $591 million associated with the movement, effective on January 1, 2018, of
                certain product offerings from the Medical segment to the Interventional segment.


              BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS - INTERNATIONAL
    Twelve Months Ended September 30, (continued)
    (Unaudited; Amounts in millions)




                                                                                                                                                                                                           D=(A-B)/B                        E=(A-B-
                                                                                                                                                                                                                                              C)/B



                                                                                         
              A                       
              B                 
              C                                         
              % Change



                                                                                                 2018                                2017                         FX Impact                                  Reported                           FXN




              
                BD MEDICAL

    ---


              Medication Delivery Solutions (a)                                                        $
              1,752                                                    $
              1,434                                                           $
        52        22.2           18.5



              Medication Management Solutions                                                    513                                           452                                                                 25                                        13.6         8.0



              Diabetes Care                                                                      541                                           510                                                                 17                                         6.0         2.6



              Pharmaceutical Systems                                                           1,040                                           929                                                                 60                                        12.0         5.5



              TOTAL                                                                                    $
              3,846                                                    $
              3,325                                                          $
        155        15.7           11.0






              
                BD LIFE SCIENCES

    ---


              Preanalytical Systems                                                                      $
              792                                                      $
              730                                                           $
        21         8.5            5.7



              Diagnostic Systems                                                                 858                                           756                                                                 26                                        13.5        10.1



              Biosciences                                                                        766                                           684                                                                 24                                        11.9         8.3



              TOTAL                                                                                    $
              2,416                                                    $
              2,170                                                           $
        71        11.3            8.1






              
                BD INTERVENTIONAL

    ---


              Surgery (a)                                                                                $
              245                                                       $
              89                                                           $
        11      
       NM         
      NM



              Peripheral Intervention (a)                                                        451                                             6                                                                 20                                       
          NM          
      NM



              Urology and Critical Care                                                          256                                                                                                              11                                       
          NM          
      NM



              TOTAL                                                                                      $
              953                                                       $
              95                                                           $
        43      
       NM         
      NM






              TOTAL INTERNATIONAL                                                                      $
              7,215                                                    $
              5,589                                                          $
        269        29.1           24.3






              (a)  The presentation of prior-period amounts reflects a reclassification of $95 million associated with the movement, effective on January 1, 2018, of certain product offerings from the Medical segment to the Interventional segment.


              BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS - TOTAL
    Twelve Months Ended September 30, (continued)
    (Unaudited; Amounts in millions)




                                                                                                                                                                                                             D=(A-B)/B                        E=(A-B-
                                                                                                                                                                                                                                                C)/B



                                                                                         
              A                        
              B                 
              C                                          
              % Change



                                                                                                 2018                                 2017                         FX Impact                                   Reported                           FXN




              
                BD MEDICAL

    ---


              Medication Delivery Solutions (a)                                                         $
              3,644                                                     $
              2,812                                                           $
        52        29.6           27.7



              Medication Management Solutions                                                  2,470                                          2,295                                                                  25                                         7.7         6.6



              Diabetes Care                                                                    1,105                                          1,056                                                                  17                                         4.6         2.9



              Pharmaceutical Systems                                                           1,397                                          1,256                                                                  60                                        11.2         6.4



              TOTAL                                                                                     $
              8,616                                                     $
              7,419                                                          $
        155        16.1           14.0






              
                BD LIFE SCIENCES

    ---


              Preanalytical Systems                                                                     $
              1,553                                                     $
              1,471                                                           $
        21         5.5            4.1



              Diagnostic Systems                                                               1,536                                          1,378                                                                  26                                        11.5         9.6



              Biosciences                                                                      1,241                                          1,139                                                                  24                                         9.0         6.8



              TOTAL                                                                                     $
              4,330                                                     $
              3,988                                                           $
        71         8.6            6.8






              
                BD INTERVENTIONAL

    ---


              Surgery (a)                                                                               $
              1,192                                                       $
              666                                                           $
        11      
       NM         
      NM



              Peripheral Intervention (a)                                                      1,045                                             19                                                                  20                                       
          NM          
      NM



              Urology and Critical Care                                                          800                                                                                                                11                                       
          NM          
      NM



              TOTAL                                                                                     $
              3,037                                                       $
              685                                                           $
        43      
       NM         
      NM






              TOTAL REVENUES                                                                           $
              15,983                                                    $
              12,093                                                          $
        269        32.2           29.9






              (a)  The presentation of prior-period amounts reflects a reclassification of $685 million associated with the movement, effective on January 1, 2018, of certain product offerings from the Medical segment to the Interventional segment.


              BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL INFORMATION
    RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE REVENUE CHANGE - UNITED STATES
    Three Months Ended September 30,
    (Unaudited; Amounts in millions)






                                                                                           
          A                 
            B             
         C                 
            D         
            E                  F=B+C+D+E          G=(A-F)/F



                                                                                             BD Reported              BD Reported (a)        Bard (b)                 Intercompany        Divestiture             Comparable       Comparable %
                                                                                                                                                                                                                                       Change

                                                                                                                                                                     Adjustment (c)     Adjustments (d)



                                                                                                    2018                          2017             2017                                               2017




              
                BD MEDICAL

    ---


              Medication Delivery Solutions (a)                                                           $
       512                                       $
       352                                         $
     143                  $
              (3)       
      $                 $
       491  4.4



              Medication Management Solutions                                                       542                               440                                                                                                         440                23.2



              Diabetes Care                                                                         149                               147                                                                                                         147                 1.7



              Pharmaceutical Systems                                                                118                                96                                                                                                          96                22.1



              TOTAL                                                                                     $
       1,322                                     $
       1,035                                         $
     143                  $
              (3)       
      $               $
       1,174 12.6






              
                BD LIFE SCIENCES

    ---


              Preanalytical Systems                                                                       $
       196                                       $
       189                           
              $                    
      $                       
      $                 $
       189  3.7



              Diagnostic Systems                                                                    159                               151                                                                                                         151                 5.9



              Biosciences                                                                           125                               123                                                                                                         123                 1.6



              TOTAL                                                                                       $
       481                                       $
       463                           
              $                    
      $                       
      $                 $
       463  3.8






              
                BD INTERVENTIONAL

    ---


              Surgery (a)                                                                                 $
       259                                       $
       143                                         $
     122             
      $                            $
     (10)         $
       256  1.5



              Peripheral Intervention (a)                                                           201                                 3                                        184                                                               187                 7.2



              Urology and Critical Care                                                             186                                                                         172                                                               172                 8.3



              TOTAL                                                                                       $
       646                                       $
       146                                         $
     478             
      $                            $
     (10)         $
       614  5.1






              TOTAL UNITED STATES                                                                       $
       2,448                                     $
       1,644                                         $
     621                  $
              (4)            $
     (10)       $
       2,251  8.7



              (a)                  Reflects a reclassification of $146
                                     million associated with the
                                     movement, effective on January 1,
                                     2018, of certain product offerings
                                     from the Medical segment to the
                                     Interventional segment.



              (b)                  Amounts presented in alignment with
                                     BD's current-period segment,
                                     organizational unit and regional
                                     reporting structure.  Also reflects
                                     the elimination of revenues from
                                     the Peripheral Intervention unit
                                     related to a royalty income stream,
                                     reported as revenues by Bard, which
                                     BD reports as non-operating income
                                     in the current-year period.



              (c)                  Represents the elimination of
                                     revenues from the Medication
                                     Delivery Solutions unit which BD
                                     previously recognized from Bard as
                                     third-party revenues and that
                                     would be treated as intercompany
                                     revenues in the current-year
                                     period.



              (d)                  Represents adjustments for BD's
                                     divestiture of its soft tissue core
                                     needle biopsy product line and
                                     Bard's divestiture of its Aspira(R)
                                     product line.


              BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL INFORMATION
    RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE REVENUE CHANGE - INTERNATIONAL
    Three Months Ended September 30, (continued)
    (Unaudited; Amounts in millions)






                                                                                           
          A                  
            B             
         C                  
            D                 E=B+C+D            
         F             G=(A-E-F)/E



                                                                                             BD Reported               BD Reported (a)        Bard (b)                   Divestiture          Comparable             FX Impact         FXN % Change

                                                                                                                                                                       Adjustments (c)



                                                                                                    2018                           2017             2017                                 2017




              
                BD MEDICAL

    ---


              Medication Delivery Solutions (a)                                                           $
        454                                       $
        369                                        $
      64              
        $                        $
        434        $
       (12)  7.6



              Medication Management Solutions                                                       149                                131                                                                                       131                  (1)              15.0



              Diabetes Care                                                                         135                                136                                                                                       136                  (3)               1.8



              Pharmaceutical Systems                                                                285                                271                                                                                       271                    1                4.9



              TOTAL                                                                                     $
        1,025                                       $
        908                                        $
      64              
        $                        $
        972        $
       (16)  7.0






              
                BD LIFE SCIENCES

    ---


              Preanalytical Systems                                                                       $
        197                                       $
        189                          
              $                     
        $                        $
        189         $
       (8)  8.6



              Diagnostic Systems                                                                    224                                208                                                                                       208                  (5)               9.8



              Biosciences                                                                           206                                191                                                                                       191                  (3)               9.6



              TOTAL                                                                                       $
        627                                       $
        588                          
              $                     
        $                        $
        588        $
       (15)  9.3






              
                BD INTERVENTIONAL

    ---


              Surgery (a)                                                                                  $
        69                                        $
        24                                        $
      41                     $
              (3)         $
        63         $
       (1) 10.5



              Peripheral Intervention (a)                                                           148                                  2                                          136                                           138                  (1)               8.1



              Urology and Critical Care                                                              85                                                                             81                                            81                                    5.5



              TOTAL                                                                                       $
        302                                        $
        26                                       $
      258                     $
              (3)        $
        282         $
       (2)  7.9






              TOTAL INTERNATIONAL                                                                       $
        1,954                                     $
        1,522                                       $
      323                     $
              (3)      $
        1,842        $
       (33)  7.9



              (a)                  Reflects a reclassification of $26
                                     million associated with the
                                     movement, effective on January 1,
                                     2018, of certain product offerings
                                     from the Medical segment to the
                                     Interventional segment.



              (b)                  Amounts presented in alignment with
                                     BD's current-period segment,
                                     organizational unit and regional
                                     reporting structure.



              (c)                  Represents adjustments for BD's
                                     divestiture of its soft tissue core
                                     needle biopsy product line and
                                     Bard's divestiture of its Aspira(R)
                                     product line.


              BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL INFORMATION
    RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE REVENUE CHANGE - TOTAL
    Three Months Ended September 30, (continued)
    (Unaudited; Amounts in millions)




                                                                                   
          A                 
            B             
         C                 
            D         
            E                  F=B+C+D+E        
            G        H=(A-F-G)/F



                                                                                     BD Reported              BD Reported (a)        Bard (b)                 Intercompany        Divestiture             Comparable            FX Impact    FXN % Change

                                                                                                                                                             Adjustment (c)     Adjustments (d)



                                                                                            2018                          2017             2017                                               2017




              
                BD MEDICAL

    ---


              Medication Delivery Solutions (a)                                                   $
       967                                       $
       721                                         $
     207                    $
              (3)                  
      $                 $
        925        $
       (12)  5.9



              Medication Management Solutions                                               692                               571                                                                                                                      571                (1)               21.3



              Diabetes Care                                                                 285                               283                                                                                                                      283                (3)                1.7



              Pharmaceutical Systems                                                        403                               367                                                                                                                      367                  1                 9.4



              TOTAL                                                                             $
       2,346                                     $
       1,943                                         $
     207                    $
              (3)                  
      $               $
        2,146        $
       (16) 10.1






              
                BD LIFE SCIENCES

    ---


              Preanalytical Systems                                                               $
       393                                       $
       378                           
              $                    
      $                                    
      $                 $
        378         $
       (8)  6.1



              Diagnostic Systems                                                            384                               359                                                                                                                      359                (5)                8.2



              Biosciences                                                                   331                               314                                                                                                                      314                (3)                6.4



              TOTAL                                                                             $
       1,108                                     $
       1,051                           
              $                    
      $                                    
      $               $
        1,051        $
       (15)  6.9






              
                BD INTERVENTIONAL

    ---


              Surgery (a)                                                                         $
       328                                       $
       167                                         $
     163             
      $                                         $
     (13)         $
        318         $
       (1)  3.3



              Peripheral Intervention (a)                                                   348                                 5                                        320                                                                            325                (1)                7.6



              Urology and Critical Care                                                     271                                                                         253                                                                            253                                   7.4



              TOTAL                                                                               $
       948                                       $
       172                                         $
     736             
      $                                         $
     (13)         $
        896         $
       (2)  6.0






              TOTAL REVENUES                                                                    $
       4,402                                     $
       3,166                                         $
     943                    $
              (4)                       $
     (13)       $
        4,093        $
       (33)  8.4



              (a)                  Reflects a reclassification of $172
                                     million associated with the
                                     movement, effective on January 1,
                                     2018, of certain product offerings
                                     from the Medical segment to the
                                     Interventional segment.



              (b)                  Amounts presented in alignment with
                                     BD's current-period segment,
                                     organizational unit and regional
                                     reporting structure.  Also reflects
                                     the elimination of revenues from
                                     the Peripheral Intervention unit
                                     related to a royalty income stream,
                                     reported as revenues by Bard, which
                                     BD reports as non-operating income
                                     in the current-year period.



              (c)                  Represents the elimination of
                                     revenues from the Medication
                                     Delivery Solutions unit which BD
                                     previously recognized from Bard as
                                     third-party revenues and that
                                     would be treated as intercompany
                                     revenues in the current-year
                                     period.



              (d)                  Represents adjustments for BD's
                                     divestiture of its soft tissue core
                                     needle biopsy product line and
                                     Bard's divestiture of its Aspira(R)
                                     product line.


              BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL INFORMATION
    RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE REVENUE CHANGE - UNITED STATES
    Twelve Months Ended September 30,
    (Unaudited; Amounts in millions)




                                                                                           
          A                 
          B           
            C               
            D           E=A+B+C+D                
            F                  
           G      
            H              
             I          J=F+G+H+I           K=(E-J)/J



                                                                                             BD Reported              Bard Q1 (b)         Intercompany              Divestiture      Comparable                 BD Reported (a)               Bard (b)      Intercompany              Divestiture     Comparable        Comparable %
                                                                                                                                                                                                                                                                                                                            Change

                                                                                                                                         Adjustment (c)           Adjustments (d)                                                                          Adjustment (c)           Adjustments (d)



                                                                                                    2018                      2018                                             2018                      2017                        2017                                   2017




              
                BD MEDICAL

    ---


              Medication Delivery Solutions (a)                                                         $
       1,892                                      $
     145                                   $
     (3)                         
          $                                           $
              2,033                 $
              1,378       $
       572                 $
     (14)        
       $           $
       1,935   5.1



              Medication Management Solutions                                                     1,957                                                                                                                           1,957                                  1,843                                                                        1,843                   6.2



              Diabetes Care                                                                         564                                                                                                                             564                                    546                                                                          546                   3.2



              Pharmaceutical Systems                                                                357                                                                                                                             357                                    328                                                                          328                   8.9



              TOTAL                                                                                     $
       4,770                                      $
     145                                   $
     (3)                         
          $                                           $
              4,912                 $
              4,095       $
       572                 $
     (14)        
       $           $
       4,652   5.6






              
                BD LIFE SCIENCES

    ---


              Preanalytical Systems                                                                       $
       761                         
              $                            
              $                                
          $                                             $
              761                   $
              741  
     $                    
       $                
       $             $
       741   2.6



              Diagnostic Systems                                                                    678                                                                                                                             678                                    622                                                                          622                   8.9



              Biosciences                                                                           475                                                                                                                             475                                    455                                                                          455                   4.6



              TOTAL                                                                                     $
       1,914                         
              $                            
              $                                
          $                                           $
              1,914                 $
              1,818  
     $                    
       $                
       $           $
       1,818   5.3






              
                BD INTERVENTIONAL

    ---


              Surgery (a)                                                                                 $
       946                                      $
     105                      
              $                                          $
           (15)                            $
              1,036                   $
              577       $
       513           
       $                      $
     (39)   $
       1,051 (1.4)



              Peripheral Intervention (a)                                                           594                           188                                                                                                782                                     14                                 705                                       718                   8.8



              Urology and Critical Care                                                             544                           177                                                                                                721                                                                       681                                       681                   5.8



              TOTAL                                                                                     $
       2,084                                      $
     470                      
              $                                          $
           (15)                            $
              2,539                   $
              591     $
       1,899           
       $                      $
     (39)   $
       2,451   3.6






              TOTAL UNITED STATES                                                                       $
       8,768                                      $
     614                                   $
     (3)                                   $
           (15)                            $
              9,364                 $
              6,504     $
       2,471                 $
     (14)              $
     (39)   $
       8,921   5.0



              (a)                 Reflects a reclassification of $591
                                    million associated with the
                                    movement, effective on January 1,
                                    2018, of certain product offerings
                                    from the Medical segment to the
                                    Interventional segment.



              (b)                 Amounts in 2018 represent revenues
                                    for the quarter ended December 31,
                                    2017; amounts in 2017 represent
                                    revenues for the quarterly periods
                                    included in BD's fiscal year 2017.
                                    Amounts presented in alignment with
                                    BD's current-period segment,
                                    organizational unit and regional
                                    reporting structure.  Also reflects
                                    the elimination of revenues from
                                    the Peripheral Intervention unit
                                    related to a royalty income stream,
                                    reported as revenues by Bard, which
                                    BD reports as non-operating income
                                    in the current-year period.



              (c)                 Represents the elimination of
                                    revenues from the Medication
                                    Delivery Solutions unit which BD
                                    previously recognized from Bard as
                                    third-party revenues and that
                                    would be treated as intercompany
                                    revenues in the current-year
                                    period.



              (d)                 Represents adjustments for BD's
                                    divestiture of its soft tissue core
                                    needle biopsy product line and
                                    Bard's divestiture of its Aspira(R)
                                    product line.


              BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL INFORMATION
    RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE REVENUE CHANGE - INTERNATIONAL
    Twelve Months Ended September 30, (continued)
    (Unaudited; Amounts in millions)




                                                                                           
          A                 
          B           
            C                   D=A+B+C        
             E         
         F      
             G                  H=E+F+G       
              I           J=(D-H-
                                                                                                                                                                                                                                                                                        I)/H



                                                                                             BD Reported              Bard Q1 (b)          Divestiture            Comparable         BD Reported (a)     Bard (b)        Divestiture           Comparable             FX Impact    FXN % Change

                                                                                                                                         Adjustments (c)                                                               Adjustments (c)



                                                                                                    2018                      2018                                      2018                     2017          2017                       2017




              
                BD MEDICAL

    ---


              Medication Delivery Solutions (a)                                                         $
       1,752                                        $
      68             
      $                                     $
              1,821                         $
              1,434                    $
       228    
       $                 $
         1,663   $
       55   6.2



              Medication Management Solutions                                                       513                                                                                          513                                452                                                                  452               25    8.0



              Diabetes Care                                                                         541                                                                                          541                                510                                                                  510               17    2.6



              Pharmaceutical Systems                                                              1,040                                                                                        1,040                                929                                                                  929               60    5.5



              TOTAL                                                                                     $
       3,846                                        $
      68             
      $                                     $
              3,915                         $
              3,325                    $
       228    
       $                 $
         3,553  $
       157   5.7






              
                BD LIFE SCIENCES

    ---


              Preanalytical Systems                                                                       $
       792                          
              $                    
      $                                       $
              792                           $
              730               
     $             
       $                   $
         730   $
       21   5.7



              Diagnostic Systems                                                                    858                                                                                          858                                756                                                                  756               26   10.1



              Biosciences                                                                           766                                                                                          766                                684                                                                  684               24    8.3



              TOTAL                                                                                     $
       2,416                          
              $                    
      $                                     $
              2,416                         $
              2,170               
     $             
       $                 $
         2,170   $
       71   8.1






              
                BD INTERVENTIONAL

    ---


              Surgery (a)                                                                                 $
       245                                        $
      49                      $
              (3)                   $
              291                            $
              89                    $
       167          $
     (10)           $
         247   $
       13  12.9



              Peripheral Intervention (a)                                                           451                           146                                                             597                                  6                  515                                              521               25    9.9



              Urology and Critical Care                                                             256                            90                                                             347                                                    320                                              320               13    4.2



              TOTAL                                                                                       $
       953                                       $
      285                      $
              (3)                 $
              1,235                            $
              95                  $
       1,003          $
     (10)         $
         1,088   $
       51   8.9






              TOTAL INTERNATIONAL                                                                       $
       7,215                                       $
      353                      $
              (3)                 $
              7,566                         $
              5,589                  $
       1,231          $
     (10)         $
         6,811  $
       279   7.0



              (a)                Reflects a reclassification of $95
                                   million associated with the
                                   movement, effective on January 1,
                                   2018, of certain product offerings
                                   from the Medical segment to the
                                   Interventional segment.



              (b)                Amounts in 2018 represent revenues
                                   for the quarter ended December 31,
                                   2017; amounts in 2017 represent
                                   revenues for the quarterly periods
                                   included in BD's fiscal year 2017.
                                   Amounts presented in alignment with
                                   BD's current-period segment,
                                   organizational unit and regional
                                   reporting structure.



              (c)                Represents adjustments for BD's
                                   divestiture of its soft tissue core
                                   needle biopsy product line and
                                   Bard's divestiture of its Aspira(R)
                                   product line.


              BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL INFORMATION
    RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE REVENUE CHANGE - TOTAL
    Twelve Months Ended September 30, (continued)
    (Unaudited; Amounts in millions




                                                                                   
          A                 
          B           
            C               
           D         E=A+B+C+D                
            F                  
           G      
            H              
              I        J=F+G+H+I      
              K           L=(E-J-
                                                                                                                                                                                                                                                                                                                                  K)/J



                                                                                     BD Reported              Bard Q1 (b)         Intercompany            Divestiture     Comparable                 BD Reported (a)               Bard (b)      Intercompany              Divestiture
                                                                                                                                                           Adjustments                                                                                                      Adjustments
                                                                                                                                                               (d)                                                                                                              (d)       Comparable            FX Impact    FXN % Change

                                                                                                                                 Adjustment (c)                                                                                                 Adjustment (c)



                                                                                            2018                      2018                                          2018                      2017                        2017                                   2017




              
                BD MEDICAL

    ---


              Medication Delivery Solutions (a)                                                  $
      3,644                                      $
     213                                $
     (3)                         
          $                                          $
              3,854                  $
              2,812                    $
       800                 $
     (14)       
       $                 $
       3,598   $
       55   5.6



              Medication Management Solutions                                             2,470                                                                                                                        2,470                                  2,295                                                                                     2,295                   25                  6.6



              Diabetes Care                                                               1,105                                                                                                                        1,105                                  1,056                                                                                     1,056                   17                  2.9



              Pharmaceutical Systems                                                      1,397                                                                                                                        1,397                                  1,256                                                                                     1,256                   60                  6.4



              TOTAL                                                                              $
      8,616                                      $
     213                                $
     (3)                         
          $                                          $
              8,826                  $
              7,419                    $
       800                 $
     (14)       
       $                 $
       8,205  $
       157   5.6






              
                BD LIFE SCIENCES

    ---


              Preanalytical Systems                                                              $
      1,553                         
              $                         
              $                                
          $                                          $
              1,553                  $
              1,471               
     $                    
       $               
       $                 $
       1,471   $
       21   4.1



              Diagnostic Systems                                                          1,536                                                                                                                        1,536                                  1,378                                                                                     1,378                   26                  9.6



              Biosciences                                                                 1,241                                                                                                                        1,241                                  1,139                                                                                     1,139                   24                  6.8



              TOTAL                                                                              $
      4,330                         
              $                         
              $                                
          $                                          $
              4,330                  $
              3,988               
     $                    
       $               
       $                 $
       3,988   $
       71   6.8






              
                BD INTERVENTIONAL

    ---


              Surgery (a)                                                                        $
      1,192                                      $
     153                   
              $                                          $
           (18)                           $
              1,327                    $
              666                    $
       680           
       $                     $
     (48)         $
       1,298   $
       13   1.3



              Peripheral Intervention (a)                                                 1,045                           334                                                                                           1,379                                     19                              1,220                                                   1,239                   25                  9.3



              Urology and Critical Care                                                     800                           267                                                                                           1,068                                                                    1,002                                                   1,002                   13                  5.3



              TOTAL                                                                              $
      3,037                                      $
     755                   
              $                                          $
           (18)                           $
              3,774                    $
              685                  $
       2,902           
       $                     $
     (48)         $
       3,539   $
       51   5.2






              TOTAL REVENUES                                                                    $
      15,983                                      $
     968                                $
     (3)                                   $
           (18)                          $
              16,930                 $
              12,093                  $
       3,702                 $
     (14)             $
     (48)        $
       15,732  $
       279   5.8



              (a)                  Reflects a reclassification of $685
                                     million associated with the
                                     movement, effective on January 1,
                                     2018, of certain product offerings
                                     from the Medical segment to the
                                     Interventional segment.



              (b)                  Amounts in 2018 represent revenues
                                     for the quarter ended December 31,
                                     2017; amounts in 2017 represent
                                     revenues for the quarterly periods
                                     included in BD's fiscal year 2017.
                                     Amounts presented in alignment with
                                     BD's current-period segment,
                                     organizational unit and regional
                                     reporting structure.  Also reflects
                                     the elimination of revenues from
                                     the Peripheral Intervention unit
                                     related to a royalty income stream,
                                     reported as revenues by Bard, which
                                     BD reports as non-operating income
                                     in the current-year period.



              (c)                  Represents the elimination of
                                     revenues from the Medication
                                     Delivery Solutions unit which BD
                                     previously recognized from Bard as
                                     third-party revenues and that
                                     would be treated as intercompany
                                     revenues in the current-year
                                     period.



              (d)                  Represents adjustments for BD's
                                     divestiture of its soft tissue core
                                     needle biopsy product line and
                                     Bard's divestiture of its Aspira(R)
                                     product line.


              BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL INFORMATION
    RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS
    (Unaudited)




                                                                                                                                 
        Three Months Ended September 30,


                                                                                             2018             2017         Growth                             Foreign    Foreign               Growth %  Foreign

                                                                                                                                                            Currency   Currency                         Currency

                                                                                                                                                          Translation  Neutral                          Neutral

                                                                                                                                                                        Growth                          Growth %




              Reported Diluted (Loss) Earnings per Share                                         $
       (0.64)                     $
        1.24                                     $
        (1.88)                    $
       (0.06)   $
        (1.82)   (151.6)    (146.8)
                                                                                                                                                                                                                                                   %          %



               Purchase accounting adjustments ($374 million and $130 million pre-tax,
                respectively) (1)                                                            1.39                     0.56


               Restructuring costs ($57 million and $30 million pre-tax, respectively)
                (2)                                                                         0.21                     0.13


               Integration costs ($88 million and $78 million pre-tax, respectively) (2)     0.33                     0.34


               Transaction costs ($(5) million and $2 million pre-tax, respectively) (3)   (0.02)                    0.01



              Financing impacts ($44 million pre-tax) (4)                                                           0.19



              Hurricane recovery costs ($2 million pre-tax)                                 0.01


               Net impact of gain on sale of investment and asset impairments ($63 million
                pre-tax) (5)                                                                 0.23


               Lease contract modification-related charge ($6 million pre-tax) (6)                                   0.03



              Litigation-related item ($(1) million pre-tax) (7)                                                  (0.01)



              Dilutive impact (8)                                                         (0.07)                    0.31


               Impact of tax reform and income tax benefit of special items ($398 million
                and $(91) million, respectively) (9)                                         1.48                   (0.39)




              Adjusted Diluted Earnings per Share                                                  $
       2.93                      $
        2.40                                       $
        0.53                     $
       (0.06)    $
         0.59       22.1        24.6
                                                                                                                                                                                                                                                   %          %



              (1)              Includes adjustments related to the
                                  purchase accounting for
                                  acquisitions impacting identified
                                  intangible assets and valuation of
                                  fixed assets and debt.



              (2)              Represents restructuring and
                                  integration costs associated with
                                  the Bard and CareFusion
                                  acquisitions, as well as
                                  restructuring costs associated
                                  with other portfolio
                                  rationalization initiatives.



              (3)              Represents transaction costs
                                  primarily associated with the Bard
                                  acquisition.



              (4)              Represents financing impacts
                                  associated with the Bard
                                  acquisition.



              (5)              Includes $58 million of charges to
                                  write down the value of fixed
                                  assets primarily in the Diabetes
                                  Care unit.



              (6)              Represents an adjustment to a non-
                                  cash charge resulting from a
                                  modification to our dispensing
                                  equipment lease contracts with
                                  customers.



              (7)              Represents an adjustment to
                                  litigation-related reserves.



              (8)              The amount in 2018 represents the
                                  exclusion of share equivalents
                                  associated with share-based plans
                                  from the reported diluted shares
                                  outstanding calculation because
                                  such equivalents would have been
                                  antidilutive due to the net loss
                                  incurred during the period.  The
                                  adjusted diluted average shares
                                  outstanding (in thousands) were
                                  274,693.  The amount in 2017
                                  represents the dilutive impact of
                                  BD shares issued in May 2017, in
                                  anticipation of the Bard
                                  acquisition.



              (9)              Includes additional tax expense,
                                  net, of $365 million relating to
                                  new U.S. tax legislation.


              BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL INFORMATION
    RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS
    (Unaudited)




                                                                                                                              
        Twelve Months Ended September 30,


                                                                                            2018           2017         Growth                             Foreign     Foreign              Growth %  Foreign

                                                                                                                                                         Currency    Currency                        Currency

                                                                                                                                                       Translation   Neutral                         Neutral

                                                                                                                                                                      Growth                         Growth %




              Reported Diluted Earnings per Share                                                $
      0.60                      $
        4.60                                      $
       (4.00)                   $
      0.32  $
        (4.32)  (87.0)   (93.9)
                                                                                                                                                                                                                                        %        %



               Purchase accounting adjustments ($1.733 billion and $491 million pre-tax,
                respectively) (1)                                                           6.55                   2.20                                                    0.01


               Restructuring costs ($344 million and $85 million pre-tax, respectively)
                (2)                                                                        1.30                   0.38                                                    0.01


               Integration costs ($344 million and $237 million pre-tax, respectively)
                (2)                                                                        1.30                   1.06                                                    0.01


               Transaction costs ($56 million and $39 million pre-tax, respectively) (3)    0.21                   0.17


               Financing impacts ($49 million and $131 million pre-tax, respectively) (4)   0.19                   0.58



              Hurricane recovery costs ($17 million pre-tax)                               0.07


               Losses on debt extinguishment ($16 million and $73 million pre-tax,
                respectively) (5)                                                           0.06                   0.33


               Net impact of gain on sale of investment and asset impairments ($(151)
                million pre-tax) (6)                                                      (0.57)                                                                         0.01


               Lease contract modification-related charge ($748 million pre-tax) (7)                              3.34



              Litigation-related item ($(337) million pre-tax) (8)                                             (1.51)



              Dilutive Impact (9)                                                          0.30                   0.54


               Impact of tax reform and income tax benefit of special items ($265 million
                and $(495) million, respectively) (10)                                      1.00                 (2.21)                                                 (0.01)




              Adjusted Diluted Earnings per Share                                               $
      11.01                      $
        9.48                                        $
       1.53                    $
      0.36    $
        1.17     16.1      12.3
                                                                                                                                                                                                                                        %        %



              (1)               Includes adjustments related to the
                                   purchase accounting for acquisitions
                                   impacting identified intangible
                                   assets and valuation of fixed assets
                                   and debt.  The amount in 2018 also
                                   included a fair value step-up
                                   adjustment of $478 million recorded
                                   relative to Bard's inventory on the
                                   acquisition date.



              (2)               Represents restructuring and
                                   integration costs associated with
                                   the Bard and CareFusion
                                   acquisitions, as well as
                                   restructuring costs associated with
                                   other portfolio rationalization
                                   initiatives.



              (3)               Represents transaction costs
                                   primarily associated with the Bard
                                   acquisition.



              (4)               Represents financing impacts
                                   associated with the Bard
                                   acquisition.



              (5)               Represents losses recognized upon the
                                   extinguishment of certain long-term
                                   senior notes.



              (6)               Represents the net amount recognized
                                   in the period related to BD's sale
                                   of its non-controlling interest in
                                   Vyaire Medical, partially offset by
                                   $81 million of charges recorded to
                                   write down the carrying value of
                                   certain intangible and other assets
                                   in the Biosciences unit as well as
                                   $58 million of charges to write down
                                   the value of fixed assets primarily
                                   in the Diabetes Care unit.



              (7)               Represents a non-cash charge
                                   resulting from a modification to our
                                   dispensing equipment lease contracts
                                   with customers.



              (8)               Represents the reversal of certain
                                   reserves related to an appellate
                                   court decision which, among other
                                   things, reversed an unfavorable
                                   antitrust judgment in the RTI case.



              (9)               Represents the dilutive impact of BD
                                   shares issued in May 2017, in
                                   anticipation of the Bard acquisition
                                   and BD shares issued as
                                   consideration transferred to acquire
                                   Bard.  The adjusted diluted average
                                   shares outstanding (in thousands)
                                   was 260,758.



              (10)              Includes additional tax expense, net,
                                   of $640 million relating to new U.S.
                                   tax legislation.


              BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL INFORMATION
    FY 2019 OUTLOOK RECONCILIATION




                                                                                                                          
             
       BD Including Bard




                                                                       FY2018                                               
             
       FY2019 Outlook



                                                                Revenues                                          % Change                      
              FX Impact   
     % Change FXN






              BDX Revenue                                                      $
         15,983                                                             8.5% to 9.5%      ~2.0%     10.5% to 11.5%






              
                Comparable Revenue Growth


                                                                       FY2018                                        FY2019 Outlook



                                                                Revenues                                        % Change FXN
                                                                                                                 Comparable






              BDX As Reported Revenue                                          $
         15,983



              Bard Q1                                                    968



              Intercompany Adjustment                                    (3)



              Divestiture Adjustment (1)(2)                            (124)



              BDX NewCo Comparable Revenue                                     $
         16,824                                                             5.0% to 6.0%




























              BECTON DICKINSON AND COMPANY


              SUPPLEMENTAL INFORMATION


              FY 2019 OUTLOOK RECONCILIATION (continued)


                                                                       FY2018                                        FY2019 Outlook



                                                                Revenues                                        % Change FXN
                                                                                                                 Comparable




              BD Medical As Reported Revenue                                    $
         8,616



              Bard Q1                                                    213



              Intercompany Adjustment                                    (3)



              BD Medical Comparable Revenue                                     $
         8,826                                                             5.0% to 6.0%








              BD Life Sciences As Reported Revenue                              $
         4,330



              Divestiture Adjustment (1)                               (106)



              BD Life Sciences Comparable Revenue                               $
         4,224                                                             4.0% to 5.0%






              BD Interventional as Reported Revenue                             $
         3,037



              Bard Q1                                                    755



              Divestiture Adjustment (2)                                (18)



              BD Interventional Comparable Revenue                              $
         3,774                                                             6.0% to 7.0%









                                                                              
         
             BD Including Bard



                                                                               
         
             FY2019 Outlook


                                                            Full Year FY2019                                     Full Year
                                                                 Outlook                                           FY2018                       
              % Increase






              Adjusted Fully Diluted Earnings per Share  
       $12.05 to 12.15                                                        $
     11.01                                 ~10%






              Estimated FX Impact                                                                                                                              ~3.5%





              Adjusted FXN Growth                                                                                                                          13% - 14%




                  FXN - Foreign Currency Neutral


              (1)              Excludes the impact from the
                                  divestiture of BD's Advanced
                                  Bioprocessing Business.



              (2)              Excludes the impact from the
                                  divestitures of BD's soft tissue
                                  core needle biopsy product line
                                  and Bard's Aspira product line of
                                  tunneled home drainage catheters
                                  and accessories.

Contact:
Monique N. Dolecki, Investor Relations - 201-847-5378
Kristen Cardillo, Corporate Communications - 201-847-5657

View original content:http://www.prnewswire.com/news-releases/bd-announces-results-for-2018-fourth-fiscal-quarter-and-full-year-provides-fiscal-2019-guidance-300744342.html

SOURCE BD (Becton, Dickinson and Company)